Indaptus Therapeutics Ownership
| INDP Stock | USD 0.72 0.04 5.26% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 9.5 M | Current Value 12 M | Avarage Shares Outstanding 211.4 M | Quarterly Volatility 913.1 M |
Indaptus |
Indaptus Stock Ownership Analysis
About 42.0% of the company shares are held by company insiders. The book value of Indaptus Therapeutics was currently reported as 0.33. The company recorded a loss per share of 1.61. Indaptus Therapeutics last dividend was issued on the 30th of October 2020. The entity had 1:4 split on the 27th of July 2021. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Indaptus Therapeutics call Jeffrey JD at 646 427 2727 or check out https://indaptusrx.com.Besides selling stocks to institutional investors, Indaptus Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Indaptus Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Indaptus Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Indaptus Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 42.0% of Indaptus Therapeutics are currently held by insiders. Unlike Indaptus Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Indaptus Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Indaptus Therapeutics' insider trades
Indaptus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Indaptus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Indaptus Therapeutics backward and forwards among themselves. Indaptus Therapeutics' institutional investor refers to the entity that pools money to purchase Indaptus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-12-31 | 3.5 K | Ubs Group Ag | 2024-12-31 | 2.5 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 884 | Bangor Savings Bank | 2024-12-31 | 400 | Wells Fargo & Co | 2024-12-31 | 64.0 | Bank Of America Corp | 2024-12-31 | 61.0 | Jpmorgan Chase & Co | 2024-12-31 | 19.0 | Group One Trading, Lp | 2024-12-31 | 7.0 | Fmr Inc | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-12-31 | 256.3 K | Investment House Llc | 2024-12-31 | 100.2 K |
Indaptus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Indaptus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Indaptus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Indaptus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Indaptus Therapeutics Outstanding Bonds
Indaptus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Indaptus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Indaptus bonds can be classified according to their maturity, which is the date when Indaptus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Pair Trading with Indaptus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Indaptus Stock
| 0.8 | LUCD | Lucid Diagnostics | PairCorr |
| 0.71 | WM | Waste Management | PairCorr |
| 0.62 | GE | GE Aerospace | PairCorr |
| 0.44 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.43 | PG | Procter Gamble | PairCorr |
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.